Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
03 Mai 2024 - 10:30PM
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
biopharmaceutical company dedicated to bringing a first-in-class
pipeline of induced pluripotent stem cell (iPSC)-derived cellular
immunotherapies to patients with cancer and autoimmune diseases,
today announced that a late-breaking abstract featuring preclinical
data from its FT522 program for autoimmune diseases will be
featured at the American Society of Gene and Cell Therapy (ASGCT)
27th Annual Meeting, being held in Baltimore,
Maryland on May 7-11, 2024.
FT522 is the Company’s CD19-targeted, iPSC-derived CAR NK cell
product candidate that incorporates its novel alloimmune defense
receptor (ADR) technology, which is designed to increase the
potency of off-the-shelf cell therapy and enable treatment without
administration of conditioning chemotherapy to patients. At the
ASGCT conference, the Company will present multiple preclinical
studies displaying the function of FT522 using peripheral blood
mononuclear cells (PBMCs) sourced from unmatched donors with
systemic lupus erythematosus (SLE). These preclinical data
demonstrate rapid and deep B-cell depletion, enhanced functional
persistence, and elimination of alloreactive host immune cells,
indicating that FT522 may deliver therapeutic benefit to patients
with autoimmune diseases without requiring administration of
conditioning chemotherapy.
Late-breaking abstracts are available on the ASGCT Annual
Meeting website. Presentation details are as follows:
PresentationFT522: A CAR NK Cell with
the Unique Ability to Target Multiple Pathogenic Cell Types and
Circumvent Lympho-conditioning in Systemic
AutoimmunityLate-Breaking Abstract Number: LBA-35Session:
Late-Breaking AbstractsLocation: Exhibit HallPresentation Date /
Time: Thursday, May 9, 2024 12:00 PM
About Fate Therapeutics’ iPSC Product
PlatformHuman induced pluripotent stem cells (iPSCs)
possess the unique dual properties of unlimited self-renewal and
differentiation potential into all cell types of the body. The
Company’s proprietary iPSC product platform combines
multiplexed-engineering of human iPSCs with single-cell selection
to create clonal master iPSC lines. Analogous to master cell lines
used to mass produce biopharmaceutical drug products such as
monoclonal antibodies, the Company utilizes its clonal master iPSC
lines as a starting cell source to manufacture engineered cell
products which are well-defined and uniform in composition, can be
stored in inventory for off-the-shelf availability, can be combined
and administered with other therapies, and can potentially reach a
broad patient population. As a result, the Company’s platform is
uniquely designed to overcome numerous limitations associated with
the manufacture of cell therapies using patient- or donor-sourced
cells. Fate Therapeutics’ iPSC product platform is supported by an
intellectual property portfolio of over 500 issued patents and 500
pending patent applications.
About Fate Therapeutics, Inc.Fate Therapeutics
is a clinical-stage biopharmaceutical company dedicated to bringing
a first-in-class pipeline of induced pluripotent stem cell
(iPSC)-derived cellular immunotherapies to patients with cancer and
autoimmune diseases. Using its proprietary iPSC product platform,
the Company has established a leadership position in creating
multiplexed-engineered master iPSC lines and in the manufacture and
clinical development of off-the-shelf, iPSC-derived cell products.
The Company’s pipeline includes iPSC-derived natural killer (NK)
cell and T-cell product candidates, which are selectively designed,
incorporate novel synthetic controls of cell function, and are
intended to deliver multiple therapeutic mechanisms to patients.
Fate Therapeutics is headquartered in San Diego, CA. For more
information, please visit www.fatetherapeutics.com.
Forward-Looking StatementsThis release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 including statements
regarding the advancement of and plans related to the Company's
product candidates, clinical studies and preclinical research and
development programs, the Company’s progress, plans and timelines
for the clinical investigation of its product candidates, including
the initiation and continuation of enrollment in the Company’s
clinical trials, the timing and availability of data from the
Company’s clinical trials, the therapeutic and market potential of
the Company’s research and development programs and product
candidates, and the potential capabilities and benefits of the
Company’s iPSC product platform. These and any other
forward-looking statements in this release are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that the
Company’s research and development programs and product candidates,
including those product candidates in clinical investigation, may
not demonstrate the requisite safety, efficacy, or other attributes
to warrant further development or to achieve regulatory approval,
the risk that results observed in prior studies of the Company’s
product candidates, including preclinical studies and clinical
trials, will not be observed in ongoing or future studies involving
these product candidates, the risk of a delay or difficulties in
the manufacturing of the Company’s product candidates or in the
initiation and conduct of, or enrollment of patients in, any
clinical trials, the risk that the Company may cease or delay
preclinical or clinical development of any of its product
candidates for a variety of reasons (including requirements that
may be imposed by regulatory authorities on the initiation or
conduct of clinical trials, changes in the therapeutic, regulatory,
or competitive landscape for which the Company’s product candidates
are being developed, the amount and type of data to be generated or
otherwise to support regulatory approval, difficulties or delays in
patient enrollment and continuation in the Company’s ongoing and
planned clinical trials, difficulties in manufacturing or supplying
the Company’s product candidates for clinical testing, failure to
demonstrate that a product candidate has the requisite safety,
efficacy, or other attributes to warrant further development, and
any adverse events or other negative results that may be observed
during preclinical or clinical development), and the risk that its
product candidates may not produce therapeutic benefits or may
cause other unanticipated adverse effects. For a discussion of
other risks and uncertainties, and other important factors, any of
which could cause the Company’s actual results to differ from those
contained in the forward-looking statements, see the risks and
uncertainties detailed in the Company’s periodic filings with the
Securities and Exchange Commission, including but not limited to
the Company’s most recently filed periodic report, and from time to
time in the Company’s press releases and other investor
communications. Fate Therapeutics is providing the information in
this release as of this date and does not undertake any obligation
to update any forward-looking statements contained in this release
as a result of new information, future events or otherwise.
Contact:Christina TartagliaStern Investor
Relations, Inc.212.362.1200christina.tartaglia@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024